Using ultrasound to guide treatment for heart failure patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the feasibility, safety, and effectiveness of using venous ultrasound (VExUS) to guide organ decongestion in patients hospitalized with acute decompensated heart failure (ADHF). A total of 180 patients will be randomly assigned to either the VExUS intervention group, where treatment decisions are informed by ultrasound results, or a standard of care group, where no such information is provided. The study aims to determine if VExUS can help manage venous congestion, a potential risk factor in ADHF. Participants will be monitored every other day during hospitalization, with follow-up assessments conducted six months post-discharge.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 18 years of age or above
* Admitted the ward of Department of Cardiology OUH Ullevål with a clinical diagnosis of ADHFdefined by European Society of Cardiology
* Pro-BNP \> 800 ng/l at first day of admission
* Capable of giving signed informed consent

Exclusion Criteria:

\- Any medical or psychiatric condition which in the opinion of the investigatorprecludes participation

Where it's running

• Department of Nephrology, Oslo University Hospital
  Oslo, Norway Recruiting

Study contacts

• Study coordinator: Bård Waldum-Grevbo, MD, PhD
• Email: uxwabr@ous-hf.no
• Phone: +4722119220

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparing Aortix Device to Diuretics for Acute Heart Failure

  This study is testing whether the Aortix device can help people with acute heart failure who aren't responding to diuretics feel better compared to standard treatment.

  Recruiting at 33 sites Procyrion · Phoenix, Arizona and 49 other locations · NCT05677100

• Using the SGLT2 pill dapagliflozin for hospitalized adults with heart failure who develop acute kidney injury.

  This trial will test whether adding the SGLT2 pill dapagliflozin to usual care helps hospitalized adults with heart failure who develop acute kidney injury.

  Recruiting at 2 sites Phase 2 Yale University · New Haven, Connecticut and 1 other locations · NCT07273838

• Using Apple Watch data to predict heart failure outcomes

  This study is testing if data from Apple Watches can help predict heart failure problems and the chances of needing to go back to the hospital for patients with heart failure.

  Recruiting University Medical Center Goettingen · Goettigen, Lower Saxony · NCT06819618

• Using remote ischemic preconditioning to protect kidneys and heart in heart failure patients

  This study is testing if a special treatment called remote ischemic preconditioning can help protect the kidneys and heart of heart failure patients during cardiac procedures.

  Recruiting at 3 sites Phase 2/3 VA Office of Research and Development · Pittsburgh, Pennsylvania and 2 other locations · NCT04982419

• Investigating blood proteins related to heart failure

  This study is trying to see if two specific proteins in the blood can help identify when people with heart failure are having a worsening episode.

  Recruiting UConn Health · Farmington, Connecticut · NCT00762008

• Myocardial Energetics Across Cardiovascular Disease Spectrum Using 31P-MRS

  Researchers are testing whether phosphorus-31 magnetic resonance spectroscopy (31P-MRS) can map heart energy metabolism across healthy people and patients with various heart conditions.

  Recruiting Chinese Academy of Medical Sciences, Fuwai Hospital · Beijing · NCT07912086

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.